Cited by 416Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes Management and Research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Open access

Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., Kendall, D. M.·2006·Diabetes, Obesity and Metabolism

DOI 10.1111/j.1463-1326.2006.00602.x

Open this paper in CoChat — free account Open PDF

Abstract

Aim Exenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30-week placebo-controlled trials. This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET). Methods This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total. Patients continued their SU and/or MET regimens throughout. Results Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age 56 +/- 10 years, weight 99 +/- 21 kg, body mass index 34 +/- 6 kg/m2, A1C 8.3 +/- 1.0% (mean +/- SD)]. Reduction in A1C from baseline to week 30 [-0.9 +/- 0.1% (mean +/- SE)] was sustained to week 82 (-1.1 +/- 0.1%), with 48% of patients achieving A1C Conclusion In summary, 82 weeks of adjunctive exenatide treatment in patients with DM2 treated with SU and/or MET resulted in sustained reduction in A1C and progressive reduction in weight, as well as improvement in some cardiovascular risk factors.

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2006.00602.x

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citation
Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citation
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citation
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Diabetes trends in the U.S.: 1990-1998.
Mokdad, A. H., Ford, E. S., Bowman, B. A., Nelson, D. E., Engelgau, M. M., Vinicor, F., & Marks, J. S. (2000) · Diabetes Care · doi:10.2337/diacare.23.9.1278 · Cited by 1,042
World Medical Association Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects
(1997) · JAMA · doi:10.1001/jama.1997.03540350075038 · Cited by 1,023

Show all 31 references

Sorted by citations

Items 101–200 of 414

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
Mikhail, N. E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.845 · Cited by 63
The Impact of Body Weight on Patient Utilities with or without Type 2 Diabetes: A Review of the Medical Literature
Dennett, S. L., Boye, K. S., & Yurgin, N. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00260.x · Cited by 61
Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control
Cohen, A., & Horton, E. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182068 · Cited by 62
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
Gurney, K., MacConell, L., Brown, C. J., & Han, J. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s28387 · Cited by 62
Self-citation
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.009 · Cited by 62
Self-citation
Exenatide and weight loss
Bradley, D. P., Kulstad, R., & Schoeller, D. A. (2010) · Nutrition · doi:10.1016/j.nut.2009.07.008 · Cited by 62
A Review of Weight Control Strategies and Their Effects on the Regulation of Hormonal Balance
Schwarz, N. A., Rigby, B. R., Bounty, P. L., Shelmadine, B., & Bowden, R. G. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/237932 · Cited by 66
GLP-1 and type 2 diabetes: physiology and new clinical advances
Combettes, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.003 · Cited by 61
Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
A 52‐week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity
Lomenick, J. P., Buchowski, M. S., & Shoemaker, A. H. (2016) · Obesity · doi:10.1002/oby.21493 · Cited by 58
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
Harris, K. B., & McCarty, D. J. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814558242 · Cited by 61
A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies
Barnett, A. H., Allsworth, J., Jameson, K., & Mann, R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x199691 · Cited by 57
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
Gaal, L. F. V., Gutkin, S. W., & Nauck, M. A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0804 · Cited by 58
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
Busch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 58
Investigation of the haemodynamic effects of exenatide in healthy male subjects
Mendis, B., Simpson, E., MacDonald, I., & Mansell, P. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04214.x · Cited by 56
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes
Ray, J. A., Boye, K. S., Yurgin, N., Valentine, W. J., Roze, S., McKendrick, J., Tucker, D. M. D., FOOS, V., & Palmer, A. J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x178685 · Cited by 55
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
Self-citation
Incretin agents in type 2 diabetes.
Ross, S. A., & Ékoé, J.-M. (2010) · PubMed · Cited by 50
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13358 · Cited by 53
Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Pratley, R. E. (2008) · PubMed Central · Cited by 52
Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus
Suarez, A. N., Noble, E. E., & Kanoski, S. E. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00101 · Cited by 55
Initiating Insulin Therapy in Type 2 Diabetes: Benefits of Insulin Analogs and Insulin Pens
Brunton, S. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0287 · Cited by 53
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Kang, Y. M., & Jung, C. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.258 · Cited by 51
Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo
Nathanson, D., Erdogdu, Ö., Pernow, J., Zhang, Q., & Nyström, T. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.07.003 · Cited by 51
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Drab, S. R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.609 · Cited by 51
Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
Kadowaki, T., Namba, M., Imaoka, T., Yamamura, A., Goto, W., Boardman, M. K., & Sowa, H. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00084.x · Cited by 51
Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
Liberini, C. G., Koch‐Laskowski, K., Shaulson, E. D., McGrath, L. E., Lipsky, R. K., Lhamo, R., Ghidewon, M. Y., Ling, T., Stein, L. M., & Hayes, M. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-44591-8 · Cited by 50
Incretin-based therapies: mimetics versus protease inhibitors
Brubaker, P. L. (2007) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.06.005 · Cited by 49
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
Brunell, S. C., Toth, P. P., Ramírez, G., Cobble, Chilton, & Chiquette (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37969 · Cited by 49
Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes
Hinnen, D., Nielsen, L. L., Waninger, A., & Kushner, P. (2006) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.19.6.612 · Cited by 48
Hypoglycemic pharmacological treatment of type 2 diabetes: Targeting the endothelium
Nathanson, D., & Nyström, T. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.11.016 · Cited by 48
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
Simó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., & Kiljański, J. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0279-z · Cited by 47
The Metabolic Syndrome and Cardiovascular Disease: Part 2
Jiamsripong, P., Mookadam, M., Alharthi, M. S., Khandheria, B. K., & Mookadam, F. (2008) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.00002.x · Cited by 47
Alterations in energy balance following exenatide administration
Bradley, D. P., Kulstad, R., Racine, N. M., Shenker, Y., Meredith, M., & Schoeller, D. A. (2012) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h2012-068 · Cited by 48
Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis
Flatt, P. R., Bailey, C. J., & Green, B. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522124 · Cited by 46
Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes
van Genugten, R. E., Möller-Goede, D. L., van Raalte, D. H., & Diamant, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12050 · Cited by 46
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes
Claus, T. H., Pan, C. Q., Buxton, J. M., Yang, L., Reynolds, J. C., Barucci, N., Burns, M. G., Ortiz, A. A., Roczniak, S., Livingston, J. N., et al. (2007) · Journal of Endocrinology · doi:10.1677/joe-06-0018 · Cited by 46
Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents
Cefalu, W. T., Waldman, S. A., & Ryder, S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100156 · Cited by 47
A Day in the Life of Oscar the Cat
Dosa, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078108 · Cited by 47
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
McAdam-Marx, C., White, K. N., & Gurgle, H. E. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83088 · Cited by 46
The Incretin Mimetic Exenatide as a Monotherapy in Patients with Type 2 Diabetes
Nelson, P., Poon, T., Guan, X., Schnabel, C. A., Wintle, M. E., & Fineman, M. S. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0024 · Cited by 45
Self-citation
Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome
Laugero, K. D., Stonehouse, A. H., Guss, S., Landry, J., Vu, C., & Parkes, D. G. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2008.0095 · Cited by 42
Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial
Basolo, A., Burkholder, J., Osgood, K., Graham, A. L., Bundrick, S. C., Frankl, J. A., Piaggi, P., Thearle, M. S., & Krakoff, J. A. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.017 · Cited by 46
Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care
Reid, T. (2013) · Clinical Diabetes · doi:10.2337/diaclin.31.4.148 · Cited by 44
GLP-1R Responsiveness Predicts Individual Gastric Bypass Efficacy on Glucose Tolerance in Rats
Habegger, K. M., Heppner, K. M., Amburgy, S. E., Ottaway, N., Holland, J., Raver, C., Bartley, E., Müller, T. D., Pfluger, P. T., Berger, J., et al. (2013) · Diabetes · doi:10.2337/db13-0511 · Cited by 43
Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
Watkins, J. B., Minshall, M. E., & Sullivan, S. D. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.9.726 · Cited by 43
After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 43
Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications
Alvarez, C., Lingvay, I., Vuylsteke, V., Koffarnus, R. L., & McGuire, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.143 · Cited by 42
Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
Gudipaty, L., Rosenfeld, N. K., Fuller, C. S., Gallop, R., Schutta, M. H., & Rickels, M. R. (2014) · Diabetes Care · doi:10.2337/dc14-0398 · Cited by 41
Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: An Adjunctive Treatment for Type 2 Diabetes Mellitus
Minshall, M. E., Oglesby, A. K., Wintle, M. E., Valentine, W. J., Roze, S., & Palmer, A. J. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00211.x · Cited by 40
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
Robles, G. I. (2009) · Drug Design Development and Therapy · doi:10.2147/dddt.s3321 · Cited by 41
Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight
Bonora, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01441.x · Cited by 40
The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Morales, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2508 · Cited by 41
Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
Brixner, D. I., McAdam-Marx, C., Ye, X., Boye, K. S., Nielsen, L. L., Wintle, M. E., Misurski, D. A., & Fabunmi, R. P. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01081.x · Cited by 38
Glucagon-Like Peptide 1 (GLP-1) Can Reverse AMP-Activated Protein Kinase (AMPK) and S6 Kinase (P70S6K) Activities Induced by Fluctuations in Glucose Levels in Hypothalamic Areas Involved in Feeding Behaviour
Hurtado-Carneiro, V., Sanz, C., Roncero, I., Vázquez, P., Blázquez, E., & Álvarez, E. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8239-z · Cited by 39
New technologies and therapies in the management of diabetes.
Triplitt, C. L. (2007) · PubMed · Cited by 37
Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt
Rupprecht, L. E., Mietlicki‐Baase, E. G., Zimmer, D. J., McGrath, L. E., Olivos, D. R., & Hayes, M. R. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00367.2013 · Cited by 37
Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
Woehl, A., Evans, M. L., Tetlow, A., & McEwan, P. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-24 · Cited by 37
Type 2 Diabetes: An Expanded View of Pathophysiology and Therapy
Unger, J., & Parkin, C. G. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2152 · Cited by 36
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Courtney, H., Nayar, R., Rajeswaran, C., & Jandhyala, R. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s126763 · Cited by 35
Role of glial cell-line derived neurotropic factor family receptor α2 in the actions of the glucagon-like peptides on the murine intestine
McDonagh, S. C., Lee, J., Izzo, A. A., & Brubaker, P. L. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00424.2006 · Cited by 36
The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide
Guo, X. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 39
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 35
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
Reid, T. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.1.3 · Cited by 35
Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells
Jeon, Y. K., Bae, M. J., Kim, J. I., Kim, J. H., Choi, S. J., Kwon, S. K., An, J. H., Kim, S. S., Kim, B. H., Kim, Y. K., et al. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.567 · Cited by 35
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea
Jonghe, B. C. D., Holland, R. A., Olivos, D. R., Rupprecht, L. E., Kanoski, S. E., & Hayes, M. R. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.10.031 · Cited by 35
Exenatide as a treatment for diabetes and obesity: Implications for cardiovascular risk reduction
Mafong, D. D., & Henry, R. R. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0009-z · Cited by 34
Glycemic Variability in Type 2 Diabetes Mellitus
Johnson, E. L. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_13 · Cited by 34
The Changing Landscape of Type 2 Diabetes: The Role of Incretin-Based Therapies in Managed Care Outcomes
Triplitt, C. L., McGill, J. B., Porte, D., & Conner, C. S. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-c.1 · Cited by 35
Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes
Raskin, P. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.783 · Cited by 33
Regulation of Energy Balance and Body Weight by the Brain: A Distributed System Prone to Disruption
Faulconbridge, L. F., & Hayes, M. R. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.008 · Cited by 34
Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice
PATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Patel, K., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0189 · Cited by 32
Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors
Mathieu, C., & Bollaerts, K. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01437.x · Cited by 32
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis
Glass, L. C., Qu, Y., Lenox, S. M., Kim, D. S., Gates, J. R., Brodows, R. G., TRAUTMANN, M. E., & Bergenstal, R. M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260862 · Cited by 31
Self-citation
Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
Bergenstal, R. M., Li, Y., Porter, T. K. B., Weaver, C., & Han, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12026 · Cited by 31
Self-citation
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 31
Self-citation
Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors
Boland, C. L., DeGeeter, M., Nuzum, D. S., & Tzefos, M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r444 · Cited by 32
MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis inob/obmice
Ohyama, T., Sato, K., Yamazaki, Y., Hashizume, H., Horiguchi, N., Kakizaki, S., Mori, M., Kusano, M., & Yamada, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16227 · Cited by 31
FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity
Wieder, N. W., Coraor, J., Kim, C., Sidhom, E.-H., Brown, M., Marshall, J. L., Arevalo, C., Dvela‐Levitt, M., Kost‐Alimova, M., Sieber, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.018 · Cited by 33
Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
Vilsbøll, T., & Garber, A. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30
Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T‐emerge 7 study)
Hollander, P. A., Lasko, B., Barnett, A. H., Bengus, M., Kanitra, L., Pi‐Sunyer, F. X., & Balena, R. (2013) · Obesity · doi:10.1002/oby.20042 · Cited by 30
Bone: Incretin Hormones Perceiver or Receiver?
Dicembrini, I., Mannucci, E., & Rotella, C. M. (2012) · Experimental Diabetes Research · doi:10.1155/2012/519784 · Cited by 30
Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial
Henry, R. R., Mudaliar, S. R. D., Kanitra, L., Woloschak, M., Balena, R., & for the T-Emerge 3 Study Group (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3253 · Cited by 30
Gastric stimulation for weight loss
Mizrahi, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2309 · Cited by 30
Management of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
Self-citation
Treatment with Glucagon-Like Peptide-1 Agonist Exendin-4 in a Patient with Hypothalamic Obesity Secondary to Intracranial Tumor
Simmons, J. H., Shoemaker, A. H., & Roth, C. L. (2012) · Hormone Research in Paediatrics · doi:10.1159/000339469 · Cited by 29
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes
Schnabel, C. A., Wintle, M. E., & Kolterman, O. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.1.69 · Cited by 29
An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
Edwards, K. L., Stapleton, M., Weis, J., & Irons, B. K. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0098.edw · Cited by 28
Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting
Bhushan, R., Elkind-Hirsch, K. E., Bhushan, M., Butler, W. J., Duncan, K., & Marrioneaux, O. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0090 · Cited by 28
Autonomic nervous system‐dependent and ‐independent cardiovascular effects of exendin‐4 infusion in conscious rats
Gardiner, S. M., March, J. E., Kemp, P. A., & Bennett, T. M. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.75 · Cited by 28
The role of incretins in salt-sensitive hypertension
Tanaka, T., Nangaku, M., & Nishiyama, A. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328349af9d · Cited by 28
Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk
Kennedy, L., & Peters, A. L. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.04 · Cited by 28
Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 30
Can Newer Therapies Delay the Progression of Type 2 Diabetes Mellitus?
Horton, E. S. (2008) · Endocrine Practice · doi:10.4158/ep.14.5.625 · Cited by 28
Incretins and bone: Evolving concepts in nutrient-dependent regulation of bone turnover
Yavropoulou, M. P., & Yovos, J. G. (2013) · HORMONES · doi:10.14310/horm.2002.1405 · Cited by 28
Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity
Preumont, V., Hermans, M. P., Brichard, S. M., & Buysschaert, M. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.02.001 · Cited by 27
Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations
Liang, N.-C., Bello, N. T., & Moran, T. H. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.16 · Cited by 27
The Efficacy and Tolerability of Exenatide in Comparison to Placebo; A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Nikfar, S., Abdollahi, M. R., & Salari, P. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3g883 · Cited by 27
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Glucagon-Like Peptide 1—A Cardiologic Dimension
Treiman, M., Elvekjær, M., Engstrøm, T., & Jensen, J. S. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.02.012 · Cited by 27

Authors: Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M.
Affiliations: Ochsner Medical Center (US)
Eli Lilly (Germany) (DE)
Corresponding author: Mac, S. M.
Kim, D. D.
ORCID: Blonde, L.
Han, J.
Kendall, D. M.
Venue: Diabetes, Obesity and Metabolism
Publisher: Wiley
Published: 2006-04-18
Volume: 8
Issue: 4
Pages: 436-447
ISSN: 1462-8902 (ISSN-L)
1463-1326
DOI: 10.1111/j.1463-1326.2006.00602.x
OpenAlex: W2093738306
Cited by: 416
References: 31
Citations by year: 2026: 1 · 2025: 2 · 2024: 7 · 2023: 3 · 2022: 3 · 2020: 5 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 15 · 2015: 15 · 2014: 19 · 2013: 24 · 2012: 45
FWCI: 38.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Diabetes Obesity and Metabolism (publishedVersion)
PubMed (publishedVersion)
Funders: Amylin Pharmaceuticals
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: exenatide, type 2 diabetes, incretin mimetics, HbA1c, glycemic control, weight loss, cardiovascular risk factors, sulfonylureas, metformin, adjunctive therapy, long-term treatment, nausea, hypoglycemia
MeSH terms: Exenatide, Adolescent, Adult, Aged, Blood Glucose, Blood Pressure, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Lipids, Male, Metformin, Middle Aged, Peptides, Risk Factors, Sulfonylurea Compounds, Venoms, Weight Loss, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks